-
1.
公开(公告)号:US20190241870A1
公开(公告)日:2019-08-08
申请号:US16267150
申请日:2019-02-04
申请人: IMMUSOFT CORPORATION
发明人: Mei XU , Matthew Rein SCHOLZ , Eric J. HERBIG
IPC分类号: C12N5/0781
CPC分类号: C12N5/0635 , C12N2501/2302 , C12N2501/2306 , C12N2501/231 , C12N2501/2315 , C12N2501/24 , C12N2501/52 , C12N2510/02
摘要: The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.
-
公开(公告)号:US20180305664A1
公开(公告)日:2018-10-25
申请号:US15769386
申请日:2016-10-20
发明人: Maksym A. VODYANYK , Xin ZHANG , Andrew J. BRANDL , Deepika RAJESH , Bradley SWANSON , Christie MUNN , Sarah A. BURTON , Wen Bo WANG
IPC分类号: C12N5/0783 , C12N5/0781 , C12N5/0784 , C12N15/86
CPC分类号: C12N5/0636 , C12N5/0635 , C12N5/0637 , C12N5/0638 , C12N5/0639 , C12N5/0646 , C12N5/0647 , C12N15/85 , C12N15/86 , C12N2500/38 , C12N2500/90 , C12N2501/115 , C12N2501/125 , C12N2501/145 , C12N2501/155 , C12N2501/165 , C12N2501/22 , C12N2501/2303 , C12N2501/2306 , C12N2501/2307 , C12N2501/25 , C12N2501/26 , C12N2501/60 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/605 , C12N2501/606 , C12N2501/608 , C12N2501/727 , C12N2501/998 , C12N2501/999 , C12N2506/025 , C12N2506/03 , C12N2506/09 , C12N2506/11 , C12N2506/45 , C12N2510/00 , C12N2533/50 , C12N2840/20
摘要: Provided herein are methods for the efficient in vitro differentiation of somatic cell-derived pluripotent stem cells to hematopoietic precursor cells, and the further differentiation of the hematopoietic precursor cells into immune cells of various myeloid or lymphoid lineages, particularly T cells, NK cells, and dendritic cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the hematopoietic precursor cells.
-
公开(公告)号:US20180036345A1
公开(公告)日:2018-02-08
申请号:US15721439
申请日:2017-09-29
发明人: Qizhi TANG , Jeffrey A. BLUESTONE
IPC分类号: A61K35/17 , A61K31/573 , C12N5/0781 , A61K31/5377 , A61K31/436 , C12N5/0783 , A61K39/00
CPC分类号: A61K35/17 , A61K31/436 , A61K31/5377 , A61K31/573 , A61K39/001 , A61K2300/00 , C12N5/0635 , C12N5/0637 , C12N2501/04 , C12N2501/2304 , C12N2501/515 , C12N2502/1107 , C12N2502/30
摘要: The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants.
-
公开(公告)号:US09801911B2
公开(公告)日:2017-10-31
申请号:US14382537
申请日:2013-03-01
发明人: Qizhi Tang , Jeffrey A. Bluestone
IPC分类号: C12N5/071 , C12N5/00 , C12N5/02 , A61K35/17 , A61K31/436 , A61K31/5377 , A61K31/573 , C12N5/0783 , A61K39/00 , C12N5/0781
CPC分类号: A61K35/17 , A61K31/436 , A61K31/5377 , A61K31/573 , A61K39/001 , A61K2300/00 , C12N5/0635 , C12N5/0637 , C12N2501/04 , C12N2501/2304 , C12N2501/515 , C12N2502/1107 , C12N2502/30
摘要: The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants.
-
公开(公告)号:US09731036B2
公开(公告)日:2017-08-15
申请号:US14287901
申请日:2014-05-27
申请人: Gal Markel
发明人: Gal Markel
IPC分类号: A01N63/00 , A61K48/00 , A61K51/10 , A61K49/00 , C07K16/30 , G01N33/569 , G01N33/574 , A61K38/17 , A61K35/17 , C07K14/705 , C12N5/0781 , C12N5/0783 , A61K51/04 , A61K51/08 , A61K35/12
CPC分类号: A61K51/10 , A61K35/17 , A61K38/1774 , A61K49/0004 , A61K49/0052 , A61K49/0056 , A61K49/0058 , A61K51/04 , A61K51/088 , A61K2035/122 , C07K14/70503 , C07K16/3007 , C07K2317/54 , C07K2317/732 , C12N5/0635 , C12N5/0636 , G01N33/56972 , G01N33/574 , G01N33/57492 , G01N2333/70596
摘要: The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the supression of immune responses in a targeted fashion, by increasing the functional concentration of the CEACAM1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue.
-
6.
公开(公告)号:US20170218336A1
公开(公告)日:2017-08-03
申请号:US15272051
申请日:2016-09-21
发明人: Roland Buelow
IPC分类号: C12N5/0781 , A01K67/027
CPC分类号: C12N5/0635 , A01K67/0275 , A01K67/0276 , A01K67/0278 , A01K2207/15 , A01K2217/052 , A01K2217/054 , A01K2217/072 , A01K2227/107 , A01K2267/01 , A61K39/00 , C07H21/04 , C07K14/70503 , C09K5/045 , C09K2205/126 , C12N15/79 , C12N15/85 , C12N15/8509 , C12N2510/02 , C12N2510/04 , C12N2517/02
摘要: The present invention describes transgenic animals with human(ized) immunoglobulin loci and transgenes encoding human(ized) Igα and/or Igβ sequences. Of particular interest are animals with transgenic heavy and light chain immunoglobulin loci capable of producing a diversified human(ized) antibody repertoire that have their endogenous production of Ig and/or endogenous Igα and/or Igβ sequences suppressed. Simultaneous expression of human(ized) immunoglobulin and human(ized) Igα and/or Igβ results in normal B-cell development, affinity maturation and efficient expression of human(ized) antibodies.
-
公开(公告)号:US20170188554A1
公开(公告)日:2017-07-06
申请号:US15326762
申请日:2016-04-18
发明人: JIA-WANG WANG , RICHARD F. LOCKEY
IPC分类号: A01K67/027 , G01N33/50 , G01N33/58 , C12N5/0781
CPC分类号: A01K67/0278 , A01K67/0275 , A01K2217/00 , A01K2217/072 , A01K2217/15 , A01K2217/203 , A01K2217/206 , A01K2227/105 , A01K2227/106 , A01K2267/0387 , A01K2267/0393 , C12N5/0635 , C12N15/907 , C12N2800/30 , G01N15/1459 , G01N33/5052 , G01N33/582 , G01N2015/1006 , G01N2500/10
摘要: The invention concerns a non-human animal model useful for modeling complex human diseases; compositions comprising cell populations from the animal model having different genotypes for the same gene; methods for producing the animal model; and methods for studying a phenotype using an animal model or compositions of the invention.
-
公开(公告)号:US09637540B2
公开(公告)日:2017-05-02
申请号:US14549726
申请日:2014-11-21
申请人: Elwha LLC
IPC分类号: C12N15/63 , C07K16/18 , A61K39/00 , C12N5/0781 , C07K16/00 , C07K16/10 , C07K16/12 , C07K16/30 , C07K16/44 , G01N33/68
CPC分类号: C07K16/18 , A61K39/00 , A61K2039/505 , A61K2039/5156 , C07K16/00 , C07K16/1018 , C07K16/109 , C07K16/1271 , C07K16/3069 , C07K16/44 , C07K2317/14 , C07K2317/76 , C12N5/0635 , C12N2510/00 , G01N33/6854
摘要: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen.
-
公开(公告)号:US20170107231A1
公开(公告)日:2017-04-20
申请号:US15312482
申请日:2015-05-22
申请人: Genzyme Corporation
发明人: Paul Mason , Kara Carter , Alexandra Joseph , Yiding Hu , Jill Gregory , Zhong Zhao , Christopher Yee , Mohamud Mohamud , Yibin Xiang , Sanjay Danthi , Yinyin Huang , Andrew Papoulis
IPC分类号: C07D498/10 , G01N33/50 , C12N5/0781 , C07D491/107 , G01N33/60
CPC分类号: C07D498/10 , C07D491/107 , C07D491/20 , C12N5/0635 , G01N33/5008 , G01N33/60
摘要: The invention features compounds of Formula (I), Formula (I)-A and Formula (I)-B as disclosed herein, as well as methods of synthesis, therapy, diagnostics, and assays.
-
公开(公告)号:US20160376372A1
公开(公告)日:2016-12-29
申请号:US15173186
申请日:2016-06-03
申请人: Vaccinex, Inc.
CPC分类号: C07K16/2887 , A61K39/39541 , A61K39/39558 , A61K2039/505 , C07K16/3061 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C12N5/0635 , C12N2501/599
摘要: Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.
-
-
-
-
-
-
-
-
-